Yohei Asano Norio Yamamoto Katsuhiro Hayashi Akihiko Takeuchi Shinji Miwa Kentaro Igarashi Takashi Higuchi Yuta Taniguchi Sei Morinaga Takashi Horimoto Masaharu Nakai Yoshifumi Kadono Takayuki Nojima Hiroyuki Tsuchiya
10.3389/fimmu.2022.980456
Front Immunol
2022 Sep 27;13:980456.
bone metastasis (bm) immune checkpoint inhibitor (ici) nivolumab pathological fracture renal cell carcinoma (rcc)
CC BY
https://pubmed.ncbi.nlm.nih.gov/36238308/
Bone Neoplasms / drug therapy Carcinoma, Renal Cell / drug therapy Carcinoma, Renal Cell / pathology Fractures, Spontaneous / drug therapy Kidney Neoplasms / pathology Lung Neoplasms / drug therapy
Bone Neoplasms / drug therapy Carcinoma, Renal Cell / drug therapy Carcinoma, Renal Cell / pathology Fractures, Spontaneous / drug therapy Kidney Neoplasms / pathology Lung Neoplasms / drug therapy Case Reports Aged Humans Immune Checkpoint Inhibitors / therapeutic use Ipilimumab / therapeutic use Male Nivolumab / therapeutic use Quality of Life Immune Checkpoint Inhibitors Ipilimumab Nivolumab
PMC9552178
36238308
Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors
2022